<VariationArchive VariationID="968377" VariationName="NM_000202.8(IDS):c.596_599del (p.Lys199fs)" VariationType="Deletion" Accession="VCV000968377" Version="8" RecordType="classified" NumberOfSubmissions="2" NumberOfSubmitters="2" DateLastUpdated="2024-02-20" DateCreated="2020-07-16" MostRecentSubmission="2024-02-14">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="959179" VariationID="968377">
      <GeneList>
        <Gene Symbol="IDS" FullName="iduronate 2-sulfatase" GeneID="3423" HGNC_ID="HGNC:5389" Source="submitted" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>Xq28</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="149476988" stop="149505306" display_start="149476988" display_stop="149505306" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="148560294" stop="148586883" display_start="148560294" display_stop="148586883" Strand="-" />
          </Location>
          <OMIM>300823</OMIM>
          <Haploinsufficiency last_evaluated="2020-11-10" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=IDS">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2020-11-10" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=IDS">No evidence available</Triplosensitivity>
        </Gene>
        <Gene Symbol="LOC106050102" FullName="IDS recombination region" GeneID="106050102" Source="calculated" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>Xq28</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="149486745" stop="149503070" display_start="149486745" display_stop="149503070" Strand="+" />
          </Location>
        </Gene>
      </GeneList>
      <Name>NM_000202.8(IDS):c.596_599del (p.Lys199fs)</Name>
      <CanonicalSPDI>NC_000023.11:149498215:TGTTTGT:TGT</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>Xq28</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="149498216" stop="149498219" display_start="149498216" display_stop="149498219" variantLength="4" positionVCF="149498215" referenceAlleleVCF="CTGTT" alternateAlleleVCF="C" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="148579747" stop="148579750" display_start="148579747" display_stop="148579750" variantLength="4" positionVCF="148579746" referenceAlleleVCF="CTGTT" alternateAlleleVCF="C" />
      </Location>
      <ProteinChange>K199fs</ProteinChange>
      <ProteinChange>K109fs</ProteinChange>
      <HGVSlist>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000202.8" sequenceAccession="NM_000202" sequenceVersion="8" change="c.596_599delAACA" MANESelect="true">
            <Expression>NM_000202.8:c.596_599delAACA</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000023.10" sequenceAccession="NC_000023" sequenceVersion="10" change="g.148579750_148579753del" Assembly="GRCh37">
            <Expression>NC_000023.10:g.148579750_148579753del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000023.11" sequenceAccession="NC_000023" sequenceVersion="11" change="g.149498219_149498222del" Assembly="GRCh38">
            <Expression>NC_000023.11:g.149498219_149498222del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_011900.3" sequenceAccession="NG_011900" sequenceVersion="3" change="g.12116_12119del">
            <Expression>NG_011900.3:g.12116_12119del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_042264.1" sequenceAccession="NG_042264" sequenceVersion="1" change="g.11574_11577del">
            <Expression>NG_042264.1:g.11574_11577del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000202.8" sequenceAccession="NM_000202" sequenceVersion="8" change="c.596_599del" MANESelect="true">
            <Expression>NM_000202.8:c.596_599del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000193.1" sequenceAccession="NP_000193" sequenceVersion="1" change="p.Lys199fs">
            <Expression>NP_000193.1:p.Lys199fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001166550.4" sequenceAccession="NM_001166550" sequenceVersion="4" change="c.326_329del">
            <Expression>NM_001166550.4:c.326_329del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001160022.1" sequenceAccession="NP_001160022" sequenceVersion="1" change="p.Lys109fs">
            <Expression>NP_001160022.1:p.Lys109fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_006123.5" sequenceAccession="NM_006123" sequenceVersion="5" change="c.596_599del">
            <Expression>NM_006123.5:c.596_599del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_006114.1" sequenceAccession="NP_006114" sequenceVersion="1" change="p.Lys199fs">
            <Expression>NP_006114.1:p.Lys199fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="non-coding">
          <NucleotideExpression sequenceAccessionVersion="NR_104128.2" sequenceAccession="NR_104128" sequenceVersion="2" change="n.765_768del">
            <Expression>NR_104128.2:n.765_768del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001619" Type="non-coding transcript variant" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="2089451657" DB="dbSNP" />
      </XRefList>
      <FunctionalConsequence Value="mutation affecting reading frame">
        <XRef ID="SO:1000064" DB="Sequence Ontology" />
      </FunctionalConsequence>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000202.8(IDS):c.596_599del (p.Lys199fs) AND Mucopolysaccharidosis, MPS-II" Accession="RCV001243493" Version="8">
        <ClassifiedConditionList TraitSetID="2973">
          <ClassifiedCondition DB="MedGen" ID="C0026705">Mucopolysaccharidosis, MPS-II</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2019-11-15" SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2019-11-15" NumberOfSubmissions="2" NumberOfSubmitters="2" DateCreated="2020-07-16" MostRecentSubmission="2024-02-14">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">26762690</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">7866405</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">8940265</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">9875019</ID>
        </Citation>
        <DescriptionHistory Dated="2022-08-22">
          <Description>Pathogenic/Likely pathogenic</Description>
        </DescriptionHistory>
        <DescriptionHistory Dated="2022-08-07">
          <Description>Pathogenic</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="2973" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="10834" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">IDS deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Sulfoiduronate sulfatase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">SIDS deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mucopolysaccharidosis type II</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mucopolysaccharidosis with skin involvement</ElementValue>
                <XRef ID="MONDO:0019302" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mucopolysaccharidosis type 2</ElementValue>
                <XRef ID="MONDO:0010674" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Mucopolysaccharidosis, MPS-II</ElementValue>
                <XRef ID="Mucopolysaccharidosis+type+II/4913" DB="Genetic Alliance" />
                <XRef ID="70737009" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Attenuated MPS (subtype; formerly known as mild MPS II)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Severe MPS II</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Iduronate 2-sulfatase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">I2S deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">MPS 2</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hunter Syndrome</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">MPS II</ElementValue>
                <XRef Type="MIM" ID="309900" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Preferred">MPS2</ElementValue>
                <XRef Type="MIM" ID="309900" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Mucopolysaccharidosis type II (MPS II; also known as Hunter syndrome) is an X-linked multisystem disorder characterized by glycosaminoglycan (GAG) accumulation. The vast majority of affected individuals are male; on rare occasion heterozygous females manifest findings. Age of onset, disease severity, and rate of progression vary significantly among affected males. In those with early progressive disease, CNS involvement (manifest primarily by progressive cognitive deterioration), progressive airway disease, and cardiac disease usually result in death in the first or second decade of life. In those with slowly progressive disease, the CNS is not (or is minimally) affected, although the effect of GAG accumulation on other organ systems may be early progressive to the same degree as in those who have progressive cognitive decline. Survival into the early adult years with normal intelligence is common in the slowly progressing form of the disease. Additional findings in both forms of MPS II include: short stature; macrocephaly with or without communicating hydrocephalus; macroglossia; hoarse voice; conductive and sensorineural hearing loss; hepatosplenomegaly; dysostosis multiplex; spinal stenosis; and carpal tunnel syndrome.</Attribute>
                <XRef ID="NBK1274" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="6675" />
                <XRef ID="6675" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301451</ID>
                <ID Source="BookShelf">NBK1274</ID>
              </Citation>
              <Citation Type="Translational/Evidence-based" Abbrev="EuroGenetest, 2011">
                <ID Source="PubMed">21863056</ID>
              </Citation>
              <Citation Type="general" Abbrev="Giugliani et al., 2014">
                <ID Source="PubMed">25071396</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/MPS-II.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Iduronate 2-Sulfatase Deficiency, Mucopolysaccharidosis Type II, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/MPS-II-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Mucopolysacchardosis Type II (MPSII): Decreased Iduronate 2-Sulfatase (I2S) activity, 2022</CitationText>
              </Citation>
              <XRef ID="580" DB="Orphanet" />
              <XRef ID="79388" DB="Orphanet" />
              <XRef ID="C0026705" DB="MedGen" />
              <XRef ID="MONDO:0010674" DB="MONDO" />
              <XRef Type="MIM" ID="309900" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="3096687" SubmissionDate="2021-04-29" DateLastUpdated="2021-05-01" DateCreated="2021-05-01">
        <ClinVarSubmissionID localKey="SUB9557774" submittedAssembly="GRCh38" title="SUB9557774" />
        <ClinVarAccession Accession="SCV001572769" DateUpdated="2021-05-01" DateCreated="2021-05-01" Type="SCV" Version="1" SubmitterName="Pediatrics, All India Institute of Medical Sciences, New Delhi" OrgID="508047" OrganizationCategory="clinic" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2014-07-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
          <Comment>The change c.596_599delAACA, (p.K199Rfs*13) was found to be a novel small frame-shift deletion variant in which four base deletion leads to frameshift change in the ORF of the translated peptide leading to the substitution of basic polar amino acid Lysine at 199 position by another basic polar amino acid Arginine. This leads to change in peptide sequence and formation of a stop codon 13 amino acid downstream the mutation. In silico analysis by the web tool Mutation Taster characterise it as a "Disease causing" pathogenic variant. It was detected in two families, one with two affected male sibs and other with the single affected male patient all were presented with attenuated phenotypes and hailed from Delhi.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">X-linked recessive inheritance</Attribute>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Ethnicity>INDIAN</Ethnicity>
              <GeographicOrigin>Delhi, India</GeographicOrigin>
              <Species TaxonomyId="9606">human</Species>
              <Age Type="minimum" age_unit="years">2</Age>
              <Age Type="maximum" age_unit="years">6</Age>
              <AffectedStatus>yes</AffectedStatus>
              <Gender>male</Gender>
              <FamilyData NumFamiliesWithVariant="2" />
            </Sample>
            <Method>
              <NamePlatform>ABI 3130</NamePlatform>
              <TypePlatform>Sanger sequencing</TypePlatform>
              <Description>Sanger sequencing was performed on ABI 3130 genetic analyser (Applied Biosystem, USA) capillary electrophoresis. Data was analysed by ABI sequence analysis (SeqScape version 2.5) software as well as manually by using software: Chromaspro (Version-1.7.5, Technilysium Pvt. Ltd, Australia) and FinchTV (Version 1.4.0, Geospiza, Perkinelmer, USA).</Description>
              <MethodType>research</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="3" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="Hemizygote" integerValue="3" />
            </ObservedData>
            <TraitSet DateLastEvaluated="2014-07-01" Type="Finding">
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <XRef DB="HP" ID="HP:0000280" />
              </Trait>
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <XRef DB="HP" ID="HP:0003040" />
              </Trait>
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <XRef DB="HP" ID="HP:0001433" />
              </Trait>
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <XRef DB="HP" ID="HP:0002194" />
              </Trait>
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <XRef DB="HP" ID="HP:0001249" />
              </Trait>
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <XRef DB="HP" ID="HP:0000365" />
              </Trait>
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <XRef DB="HP" ID="HP:0003116" />
              </Trait>
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <XRef DB="HP" ID="HP:0100790" />
              </Trait>
              <Comment>The age of onset of symptoms was from around 2 year in one patient and between 2-5 years in other two. The moderate severity scores and late age of onset of symptoms correlate with the moderate phenotypes of the patients. The same variant c.596_599delAACA, (p.K199Rfs*13) was detected in two families, one with two affected male sibs and other with the single affected male patient all were presented with attenuated phenotypes and hailed from Delhi.</Comment>
            </TraitSet>
            <Comment>The change c.596_599delAACA, (p.K199Rfs*13) was found to be a novel small frame-shift deletion variant in which four base deletion leads to frameshift change in the ORF of the translated peptide leading to the substitution of basic polar amino acid Lysine at 199 position by another basic polar amino acid Arginine. This leads to change in peptide sequence and formation of a stop codon 13 amino acid downstream the mutation. In silico analysis by the web tool Mutation Taster characterise it as a ""Disease causing"" pathogenic variant. It was detected in two families, one with two affected male sibs and other with the single affected male patient all were presented with attenuated phenotypes and hailed from Delhi.</Comment>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="IDS">
              <Name>iduronate 2-sulfatase</Name>
            </Gene>
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <GeneLocation>NM_000202.8:exon 5</GeneLocation>
          </Location>
          <OtherNameList>
            <Name Type="SubmitterVariantId">67-MPS</Name>
          </OtherNameList>
          <FunctionalConsequence Value="mutation affecting reading frame">
            <XRef DB="Sequence Ontology" ID="SO:1000064" URL="http://www.sequenceontology.org/browser/current_svn/term/SO:1000064" />
          </FunctionalConsequence>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000202.8:c.596_599delAACA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="309900" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB9557774</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2751758" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-14" DateCreated="2020-07-16">
        <ClinVarSubmissionID localKey="4981167|MedGen:C0026705" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001416657" DateUpdated="2024-02-14" DateCreated="2020-07-16" Type="SCV" Version="5" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-11-15">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">8940265</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">9875019</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">7866405</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">26762690</ID>
          </Citation>
          <Comment>For these reasons, this variant has been classified as Pathogenic. Loss-of-function variants in IDS are known to be pathogenic (PMID: 8940265, 9875019). This variant has been observed in individual(s) with Hunter syndrome (PMID: 7866405, 26762690). This variant is also known as 717del4 in the literature. This variant is not present in population databases (ExAC no frequency). This sequence change creates a premature translational stop signal (p.Lys199Argfs*13) in the IDS gene. It is expected to result in an absent or disrupted protein product.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="IDS" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000023.10:g.148579747_148579750del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0026705" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12508014</SubmissionName>
          <SubmissionName>SUB14200283</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="3096687" TraitType="Finding" MappingType="XRef" MappingValue="HP:0003116" MappingRef="HP">
        <MedGen CUI="C0476369" Name="Abnormal echocardiogram" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3096687" TraitType="Finding" MappingType="XRef" MappingValue="HP:0100790" MappingRef="HP">
        <MedGen CUI="C0019270" Name="Hernia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3096687" TraitType="Finding" MappingType="XRef" MappingValue="HP:0002194" MappingRef="HP">
        <MedGen CUI="C1837658" Name="Delayed gross motor development" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2751758" TraitType="Disease" MappingType="XRef" MappingValue="C0026705" MappingRef="MedGen">
        <MedGen CUI="C0026705" Name="Mucopolysaccharidosis, MPS-II" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3096687" TraitType="Finding" MappingType="XRef" MappingValue="HP:0001433" MappingRef="HP">
        <MedGen CUI="C0019214" Name="Hepatosplenomegaly" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3096687" TraitType="Disease" MappingType="XRef" MappingValue="309900" MappingRef="OMIM">
        <MedGen CUI="C0026705" Name="Mucopolysaccharidosis, MPS-II" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3096687" TraitType="Finding" MappingType="XRef" MappingValue="HP:0003040" MappingRef="HP">
        <MedGen CUI="C0022408" Name="Arthropathy" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3096687" TraitType="Finding" MappingType="XRef" MappingValue="HP:0001249" MappingRef="HP">
        <MedGen CUI="C3714756" Name="Intellectual disability" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3096687" TraitType="Finding" MappingType="XRef" MappingValue="HP:0000280" MappingRef="HP">
        <MedGen CUI="C1845847" Name="Coarse facial features" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3096687" TraitType="Finding" MappingType="XRef" MappingValue="HP:0000365" MappingRef="HP">
        <MedGen CUI="C1384666" Name="Hearing impairment" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

